Evaluation of Right Ventricular and Left Ventricular Function in Patients with Chronic Obstructive Pulmonary Disease by TDI Index
Dyspnea is the main symptom of chronic obstructive pulmonary disease (KD), so in addition to lung function, assessing treatment outcome is also a valuable outcome. To more fully assess the impact of TDI index on right ventricular and left ventricular function in patients with chronic obstructive pulmonary disease, four 1-year studies were performed. In this pooled analysis, roflumilast significantly improved the TDI index at week 52 (treatment difference, 0.327; P < 0.01). Compared with placebo, roflumilast was associated with a significantly greater TDI index and significantly fewer TDI exacerbations (increased or decreased by ≥1 unit from baseline) at week 52 (P<0.01, both There are); these significant differences appeared in the 8th week and continued until the end of the study (P < 0.05, all). At the end of the study, roflumilast had a significant increase in forced expiratory volume after bronchiectasis in 1 second compared with placebo (P < 0.05). Similar to the overall population, patients with chronic bronchitis had a slightly improved TDI lesion score at week 52, but continued to be significantly higher than placebo, regardless of whether they had a worsening history, concurrent use of short-acting muscarinic antagonists or long-acting beta 2 agonism. This analysis suggests that patients receiving roflumilast therapy to reduce the risk of exacerbation may have a slight but significant improvement in dyspnea with an improvement in lung function.